Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 25Pituitary Neoplasms 10Pheochromocytoma 10Carcinoma, Neuroendocrine 9Thyroid Neoplasms 8Sarcoma 8Thyroid Cancer, Papillary 6Paraganglioma 5Ovarian Neoplasms 5Neuroblastoma 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 4Parathyroid Neoplasms 4Pancreatic Neoplasms 4Osteosarcoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Medullary 4Adrenal Gland Neoplasms 4Thyroid Carcinoma, Anaplastic 3Stomach Neoplasms 3Prostatic Neoplasms 3Pituitary ACTH Hypersecretion 3Melanoma 3Head and Neck Neoplasms 3Cushing Syndrome 3Colorectal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer (DTC) × Endocrine × 30 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡